Title : Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.

Pub. Date : 2021 Nov

PMID : 33973232






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
2 Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens